La recesión diaria de Mirum Pharmaceuticals (MIRM) crece 11,29%: ¿qué está impulsando el impulso?

Summary
• Mirum’s stock soars 11.29% to $78.215, hitting its 52-week high of $79.95
• $68.5M private placement with TCGX announced, funding Bluejay Therapeutics acquisition
• Intraday range spans $70.76 to $79.95, signaling sharp volatility

Mirum Pharmaceuticals (MIRM) has ignited a dramatic intraday rally, surging 11.29% to $78.215 as of 20:30 ET. The move follows a $68.5M private placement with institutional investor TCGX, earmarked to fund clinical development and the pending acquisition of Bluejay Therapeutics. With the stock trading near its 52-week high and a 3.0% turnover rate, the market is reacting to strategic capital-raising and pipeline expansion, positioning MIRM as a focal point for rare disease innovation.

Private Placement and Acquisition Fuel Mirum’s Intraday Surge
Mirum’s 11.29% intraday jump is directly tied to its $68.5M private placement with TCGX, priced at $68.48 per share, and the broader $268.5M capital raise (including a prior $200M placement). These funds will accelerate clinical development and commercialization post-acquisition of Bluejay Therapeutics, a biotech focused on viral and liver diseases. The transaction, expected to close in Q1 2026, signals Mirum’s aggressive expansion into high-impact therapeutic areas, bolstering investor confidence in its rare disease pipeline and financial runway.

Options Playbook: High-Leverage Calls for Aggressive Bulls
• Technical Indicators: 200-day MA: $58.01 (below), 30-day MA: $69.45 (below), RSI: 43.25 (neutral), MACD: -0.96 (bearish), Bollinger Bands: $63.27–$74.76
• Key Levels: 52W high at $79.95 (critical resistance), 30D support at $72.05

Top Options:
• MIRM20260116C80 (Call, $80 strike, Jan 16 expiry):
- IV: 43.86% (moderate), Leverage: 23.46%, Delta: 0.477, Theta: -0.115, Gamma: 0.041, Turnover: 14,033
- Why: High leverage and gamma position it to capitalize on a breakout above $80. Projected 5% upside (to $82.12) yields a 24.3% payoff.
• MIRM20260417C85 (Call, $85 strike, Apr 17 expiry):
- IV: 45.22% (moderate), Leverage: 13.10%, Delta: 0.452, Theta: -0.044, Gamma: 0.019, Turnover: 21,834
- Why: Strong liquidity and moderate IV make it a durable play for sustained momentum. 5% upside (to $82.12) generates a 19.5% payoff.

Action: Aggressive bulls should prioritize MIRM20260116C80 for short-term volatility, while MIRM20260417C85 suits a mid-term bullish thesis. Monitor the $79.95 52W high as a psychological barrier; a break above could trigger a re-rating.

Backtest Mirum Stock Performance
The backtest of MIRM's performance following a 11% intraday surge from 2022 to now shows favorable results. The 3-Day win rate is 51.02%, the 10-Day win rate is 55.69%, and the 30-Day win rate is 59.96%, indicating a higher probability of positive returns in the short term. The maximum return during the backtest was 9.90% over 30 days, suggesting that MIRM can capitalize on intraday gains effectively.

Bullish Momentum Unlikely to Subside: Key Levels to Watch
Mirum’s intraday surge reflects strategic capital deployment and pipeline expansion, with the stock poised to test its $79.95 52-week high. Technicals suggest a short-term bullish bias, supported by rising RSI and a break above key moving averages. While the sector leader Pfizer (PFE) trails with a 1.06% gain, Mirum’s unique catalysts—Bluejay acquisition and rare disease focus—position it for outperformance. Investors should watch the $79.95 level for a breakout confirmation and consider MIRM20260116C80 for aggressive upside. Act now: Secure calls ahead of the Q1 2026 acquisition close and regulatory filings.